Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 11, 2014 08:00 ET | Source: Acasti Pharma Inc.

Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements

LAVAL, Quebec, Nov. 11, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research,...
October 20, 2014 07:59 ET | Source: Acasti Pharma Inc.

Acasti Announces Grant of Stock Options

LAVAL, Quebec, Oct. 20, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research,...
October 14, 2014 07:53 ET | Source: Acasti Pharma Inc.

Acasti Announces Second Quarter Results

LAVAL, Quebec, Oct. 14, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research,...
September 30, 2014 08:00 ET | Source: Acasti Pharma Inc.

Acasti Announces Positive Top-Line Pharmacokinetic Results

CaPre® demonstrated a near dose proportional increase with plasma EPA and DHA levels increasing as dose increases Bioavailability of CaPre® not significantly reduced when taken with...
September 29, 2014 08:00 ET | Source: Acasti Pharma Inc.

Acasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C

Statistically significant mean placebo-adjusted reduction of triglycerides of 36.4% at 1 gram and 38.6% at 2 gram daily doses of CaPre® Statistically significant reduction of 5.3% in...
July 24, 2014 07:00 ET | Source: Acasti Pharma Inc.

Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston

Phase II Open Label Trial results for prescription drug candidate, CaPre® to be presented on July 26, 2014 at 12:30 p.m. LAVAL, Quebec, July 24, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma...
July 15, 2014 17:48 ET | Source: Acasti Pharma Inc.

Acasti Announces First Quarter Results

LAVAL, Quebec, July 15, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research,...
July 09, 2014 08:00 ET | Source: Acasti Pharma Inc.

Acasti Completes Phase II Double Blind (TRIFECTA) and Pharmacokinetic Trials

LAVAL, Quebec, July 9, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development...
June 20, 2014 09:45 ET | Source: Acasti Pharma Inc.

Acasti Reports Results of Annual and Special Meeting

LAVAL, Quebec, June 20, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research,...
June 16, 2014 07:00 ET | Source: Acasti Pharma Inc.

Acasti Announces Resignation of Chief Financial Officer

LAVAL, Quebec, June 16, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research,...